MacroGenics, Inc.
Moat Score — MacroGenics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | MacroGenics' proprietary DART and TRIDENT bispecific/multispecific antibody-engineering platforms are patent-protected technology that has attracted licensing and collaboration deals with major pharmaceutical companies, representing a genuine and defensible intellectual-property moat. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech without a major marketed product, MacroGenics has no structural cost advantage over competitors -- drug discovery and clinical trials are expensive for every company in this space. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Having sold its one approved product, MARGENZA, to TerSera, MacroGenics has no current commercial pricing power of its own and depends on royalty terms already fixed in that sale. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in antibody drug discovery and development -- each program's value is independent of how many other programs or partners the company has. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a pharmaceutical partner like Incyte, Gilead, or Sanofi has built a clinical program around a MacroGenics DART/TRIDENT-derived candidate, switching to an alternative platform mid-program would be costly and disruptive, giving MacroGenics modest partner-level retention once a deal is signed. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | MacroGenics is a small clinical-stage biotech with no commercial manufacturing or sales scale, and its platform business does not benefit from the kind of efficient-scale barriers seen in capital-intensive manufacturing industries. |